Colonai uses artificial intelligence to help gastroenterologists, physicians who specialize in diseases of the digestive system, efficiently screen, detect and treat tumors during colonoscopy. The team has developed two products that can be integrated into current workflow: i) PolypSense, highlights suspicious areas in the colon that may have a tumor in the field of view and covers the physician’s blind spots, and ii) PolypSect, helps doctors define the margins between tumors and healthy tissue, to aid in achieving a complete resection.
Expert Collections containing Colonai
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Colonai is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Colonai Frequently Asked Questions (FAQ)
When was Colonai founded?
Colonai was founded in 2018.
Where is Colonai's headquarters?
Colonai's headquarters is located at 3143 Broadway, New York.
What is Colonai's latest funding round?
Colonai's latest funding round is Seed.
How much did Colonai raise?
Colonai raised a total of $30K.
Who are the investors of Colonai?
Investors of Colonai include Health Wildcatters.